- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01455480
Trial To Evaluate RPh201 In Treatment Of Partial Thickness Burn
December 5, 2016 updated by: Regenera Pharma Ltd
The objective of this Trial is to evaluate the performance of RPh201 as a treatment for the healing of partial thickness burns.
It is further postulated that deep second degree lesions will benefit from the RPh201 treatment promoting granulation and epithelialization as well as wound closure.
Study Overview
Status
Withdrawn
Intervention / Treatment
Detailed Description
The objective of this Trial is to evaluate the performance of RPh201 in the treatment of partial thickness burns (second degree superficial and deep) of less than 5%TBSA.
The additional follow up for a period of 20 weeks will be scheduled to extend the evaluation of wounds of Subjects that completed up to 3 weeks of treatment
This is to include:
- Efficacy assessment of burn improvement following the use of RPh2O1 oil solution administered topically three times per week during an overall treatment period of up to 3 weeks and at the follow-up visit at 20 weeks after end of treatment in Subjects with partial thickness burns (second degree superficial and deep) of less than 5%TBSA
- Safety evaluation of RPh201 formulated as an oil solution administered topically three times per week during an overall treatment period of up to 3 weeks in Subjects with partial thickness burns (second degree superficial and deep) of less than 5%TBSA.
Study Type
Interventional
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Tel Hashomer, Israel, 52621
- Clinic of the The Burn Unit, The Department of Plastic & Reconstructive Surgery and Medical Research Infrastructure Development and Health Services Fund by Chaim Sheba Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- The Subject is 18 years of age and older.
- The Subject has at least one burn wound or more from 1%- 5% TBSA overall.
- Subjects defined as a partial thickness burn for conservative treatment (second degree superficial and deep).
- Subjects will be eligible to participate in the Trial if their target lesion area of the edges is not more than 500-750 cm2 at baseline.
- The Subject is expected to be available for the 3 weeks Trial ambulatory treatment.
- The Subject is willing and able to adhere to the protocol regimen.
- The Subject is able to read, understand, and has signed the informed consent form.
Exclusion Criteria:
- Electrical and chemical burns wounds that are third degree or full thickness.
- Burn wounds of more than 48hours from burn event
- Presence of a systemic infection or significant local infection such as cellulites, purulent drainage, gangrene, or necrosis at the target wound site, as well as nonviable tissue, sinus tracts or tunnels that cannot be removed by debridement.
- Previous history of any illness or condition that may impair wound healing, immune deficiency or connective tissue disease (e.g., SLE, AIDS), neurological disease (e.g., multiple sclerosis), dialysis due to renal disease and active hepatic disease.
- Known history for allergy to cottonseed oil or mastic gum
- Subject is receiving, or has received within one month prior to Visit 1 any treatment known to impair wound healing, including but not limited to: corticosteroids, immuno-suppressive drugs, cytotoxic agents, radiation therapy and chemotherapy.
- Presence or suspicion of any malignancy.
- Female Subjects who are pregnant or nursing, or of childbearing potential and are not using adequate contraception.
- Participation in another clinical trial within 30 days prior to the Screening Visit or during this Trial.
- Mentally disable Subjects
- A tourist or foreigner or refugee that cannot be followed for the Trial period.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: RPh201
|
topical
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
determine the safety use of RPh201 administered topically three times a week during an overall treatment period of up to 3 weeks
Time Frame: 6 month
|
Safety evaluation - To demonstrate safety of using RPh201 oil solution in terms of type and severity of adverse events Achievement of wound closure / epithelialization of more than 75% percent of wound area in up to 3 weeks treatment
|
6 month
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Eyal Winkler, Dr. MD, Clinic of the The Burn Unit, The Department of Plastic & Reconstructive Surgery and Medical Research Infrastructure Development and Health Services Fund by Chaim Sheba Medical Center Tel Hashomer, Israel
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2011
Primary Completion (Actual)
December 1, 2011
Study Completion (Actual)
December 1, 2011
Study Registration Dates
First Submitted
October 16, 2011
First Submitted That Met QC Criteria
October 19, 2011
First Posted (Estimate)
October 20, 2011
Study Record Updates
Last Update Posted (Estimate)
December 6, 2016
Last Update Submitted That Met QC Criteria
December 5, 2016
Last Verified
December 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RGN-BWH-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Partial Thickness Burn
-
Amarantus BioScience Holdings, Inc.Amarex Clinical ResearchUnknownThermal Injury | Deep Partial-Thickness Burn | Full-Thickness BurnUnited States
-
Nanomedic Technologies Ltd.CompletedPartial Thickness BurnIsrael
-
Molnlycke Health Care ABRecruitingPartial-thickness BurnUnited States
-
University of TennesseeMedline IndustriesCompletedBurns | Partial-thickness BurnUnited States
-
KeraNetics, LLCUnited States Department of Defense; Wake Forest UniversityRecruitingPartial-thickness BurnUnited States
-
King Edward Medical UniversityUnknownPartial-thickness BurnPakistan
-
J. Peter Rubin, MDUnited States Department of Defense; Synedgen, Inc.Terminated
-
Chulalongkorn UniversityNational Science and Technology Development Agency, ThailandCompletedDeep Partial Thickness BurnThailand
-
GeneScience Pharmaceuticals Co., Ltd.Third Military Medical University; Shanghai Jiao Tong University School of... and other collaboratorsCompletedDeep Partial Thickness Burn
-
The University of Texas Medical Branch, GalvestonWithdrawnPartial-thickness BurnUnited States
Clinical Trials on RPh201, botanical drug product
-
Regenera Pharma LtdTransCom Global Ltd. (CRO)Terminated
-
Regenera Pharma LtdSyneos HealthCompletedHealthy Volunteers | Moderate to Severe Alzheimer PatientsCanada
-
Regenera Pharma LtdTerminatedNonarteritic Anterior Ischemic Optic NeuropathyUnited States
-
SK Life Science, Inc.CompletedChronic Constipation | Functional ConstipationUnited States
-
Assistance Publique - Hôpitaux de ParisActive, not recruiting
-
Assistance Publique - Hôpitaux de ParisRecruitingArtemis (DCLRE1C ) Deficient Severe Combined ImmunodeficiencyFrance
-
Lumosa Therapeutics Co., Ltd.UnknownAcute Ischemic StrokeTaiwan, United States
-
Capstone TherapeuticsCompletedScar Prevention | Scar ReductionUnited States
-
First Affiliated Hospital of Guangxi Medical UniversityGenmedicn Biopharma Ltd.RecruitingTransfusion-dependent α-ThalassemiaChina